Oxford, UK, January 29, 2025: Oxford Science Enterprises (OSE) and Cedars-Sinai Intellectual Property Company have joined forces to drive growth and expand opportunities for health-tech start-ups operating in both the US and UK. The partnership will include the ability toco-build and co-invest in health tech start-ups coming out of Oxford.
To initiate the ongoing partnership, Cedars-Sinai Intellectual Property Company and OSE have invested $2 million in Neu Health, a startup from the University of Oxford. The London-based organisation offers a digital smartphone-based neurology care platform to improve outcomes for Parkinson’s disease and dementia patients. This investment follows Neu Health’s participation in Cedars-Sinai’s 10th Accelerator program last year.
“The research produced at Oxford is of the highest calibre,” said Shlomo Melmed, MB, ChB, executive vice president of Medicine and Health Sciences and dean of the Medical Faculty at Cedars-Sinai.
“An ongoing relationship with Oxford Science Enterprises will serve our patients and also strengthen the academic and clinical missions of Cedars-Sinai.”
“We are excited to strengthen our relationship with Cedars-Sinai, a leading U.S. health system, given our shared commitment to commercialising world-leading research and building innovative businesses,” said Heather Roxborough, PhD, senior partner of Health Tech at Oxford Science Enterprises.
“This partnership plays a critical role in accelerating US market entry for our companies by providing access to invaluable commercial and clinical insights and the opportunity to test our healthcare technologies live in the US market.” - Heather Roxborough, Head of Health Tech at OSE
Through the strategic partnership, the two organisations aim to foster the growth of innovative health-tech start-ups, expand U.S. and U.K. market reach and plan future potential alliances on both sides of the Atlantic.
The Neu Health platform, backed by more than a decade of research and clinical validation by University of Oxford experts, includes a patient app linked to a care team dashboard. The platform uses unique data and artificial intelligence to translate motor and non-motor symptoms as well as cognitive and mental health abilities into objective, actionable information for clinicians. In the UK, the company is gaining rapid traction and is showing a clear impact on patient satisfaction and care quality. The company will now pilot its digital platform at Cedars-Sinai to expand and enter the U.S. market. The first 150 neurology patients are expected to start using the Neu Health app soon as part of the six-month pilot program.
"Investing in the research and technology coming out of Oxford through our partnership with Oxford Science Enterprises is the beginning of what we hope will become a long and fruitful relationship," said James D. Laur, JD, chief executive of Cedars-Sinai Intellectual Property Company. “Together, we can work on furthering Cedars-Sinai’s mission of providing patients around the world the best care possible.”
About Oxford Science Enterprises
Oxford Science Enterprises (OSE) is an independent, billion-pound investment company that finds, funds and builds transformational science and technology companies emerging from Oxford’s world-leading research. Our portfolio of companies are focused across three high-impact sectors – Deep Tech, Life Sciences and Health Tech – with the ambition of tackling some of the world’s greatest challenges.
To date, OSE has collaborated with over 300 international investors, collectively investing over £2.5 billion in more than 100 groundbreaking companies.